Testing a new inhaled treatment to reduce lung infection flare-ups

Plain-English translation of NCT07048262 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , an inhaled immunoglobulin treatment designed to help people with a lung condition called non-cystic fibrosis bronchiectasis. The study will compare two different doses of this medication against a placebo (a dummy treatment with no active ingredient) to see which dose works best and is safest. Researchers hope the medication will reduce how often patients experience flare-ups of lung infections.

Non-cystic fibrosis bronchiectasis is a condition where the airways in the lungs are damaged, making them more prone to infections and flare-ups. Currently, there are limited treatment options to prevent these flare-ups, so researchers are testing whether this new inhaled treatment could help protect the lungs and keep patients healthier.

Do you qualify?

You likely qualify if…

you are between 18 and 85 years old
you have been diagnosed with non-cystic fibrosis bronchiectasis, confirmed by a CT scan of your chest
you have experienced at least 2 lung infection flare-ups requiring antibiotics in the past year, or 1 flare-up plus moderate respiratory symptoms
your lung function meets minimum requirements (FEV1 at least 35% predicted and at least 1 liter)
you are willing to be randomly assigned to receive either the medication or placebo for 6 to 12 months

You likely don't qualify if…

you have had a previous bad reaction to inhaled treatments or inhaled antibiotics
you are allergic to immunoglobulin products or any ingredients in the study treatment
you have been diagnosed with other primary lung conditions like COPD, asthma, or diffuse panbronchiolitis
you had a lung infection flare-up requiring antibiotics within the 4 weeks before the study starts

What participation looks like

If you join, you will be randomly assigned to receive either a high dose of the medication, a low dose of the medication, or a placebo — all given by inhalation. You will use your assigned treatment regularly over a 6- to 12-month period while researchers track how often you experience lung infection flare-ups and monitor your lung health through breathing tests and check-ins. The study takes place at multiple hospitals or clinics, and you will have regular visits to ensure the treatment is working and is safe for you.

AI-generated summary from trial data · Jun 8, 2026 · Not medical advice

Trial locations(13 sites)

Australia

The Prince Charles Hospital, Queensland

Westmead Hospital, Westmead

Japan

Fukuoka University Chikushi Hopsital, Chikushino-shi

Kyusho Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka

Ibaraki Prefectural Central Hospital, Ibaraki